
Opinion|Videos|January 13, 2025
Main Conference Takeaways Regarding cGVHD Management
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses the key results from recent chronic graft-vs-host disease (cGVHD) research presented at ASH 2024 and how these findings will influence his clinical practice. He also shares his main takeaways on evolving strategies for cGVHD management.
Advertisement
Video content above is prompted by the following:
- What were the key results seen in this abstract and will they carry over to your clinical practice?
- What were your main takeaways with regard to chronic graft-vs-host disease management from ASH 2024?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
2
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
3
Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD
4
Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL
5








































